Video

Dr. Gitlitz Discusses the Genomics of Young Lung Cancer Study

Barbara J. Gitlitz, MD, from the University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.

Barbara J. Gitlitz, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.

This study showed that it is feasible to think outside the box when considering patient recruitment. In this study, researchers used social media and the Internet to recruit patients. In total, Gitlitz says, 44% of patients came through these means.

Researchers greatly exceeded their statistical expectations, Gitlitz says. For patients with lung adenocarcinoma, researchers set a bar close to the Lung Cancer Mutation Consortium and wanted to demonstrate an increase in actionable mutations from 35% to 50%. In actuality, they found actionable mutations in 76% of patients.

<<<

View more from the 2015 World Conference on Lung Cancer

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.